TNF and neoplasm: The first completed trial of the COTC is an example of a pharmacodynamically focused study conducted to directly inform next step decisions in the clinical development of an adeno-associated virus phage [10], [11], [12] delivery of tumor necrosis factor-α (RGD-A-TNF) to αV integrins to tumor and tumor-associated vascular endothelium.